Caris Life Sciences, Inc. Common Stock vs. Exagen Inc. Common Stock
CAI
Caris Life Sciences, Inc. Common Stock
$29.98 -3.04%
VS XGNExagen Inc. Common Stock
$8.41 +6.86%
Caris Life Sciences, Inc. Common Stock (CAI) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| CAI | XGN | |
|---|---|---|
| Market Cap | $8.74 billion | $203.74 million |
| Revenue (TTM) | $989.61 million | $71.12 million |
| Net Income (TTM) | $105.14 million | $-18,923,000 |
CAI leads on 3 of 3 size & scale factors.
Valuation
| CAI | XGN | |
|---|---|---|
| P/E Ratio | 17.74 | — |
| Price / Book | 14.77 | 16.68 |
| Price / Sales | 8.83 | 2.86 |
CAI and XGN split the valuation factors evenly.
Profitability
| CAI | XGN | |
|---|---|---|
| Net Margin | 10.62% | -26.61% |
| Return on Equity | 17.77% | -154.90% |
CAI leads on 2 of 2 profitability factors.
Dividend
| CAI | XGN | |
|---|---|---|
| Dividend Yield | 4.00% | — |
| Payout Ratio | 71.01 | — |
CAI and XGN split the dividend factors evenly.
Risk & Sentiment
| CAI | XGN | |
|---|---|---|
| Short Interest | 0.13% | 0.02% |
XGN leads on 1 of 1 risk & sentiment factors.
Dig deeper: CAI overview, CAI financials, XGN overview, XGN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.